Poor
Mostly Aligned
Patient Risk:
Low
Summary
The AI claims largely concern general skin wound use of Neosporin, which is outside the ophthalmic label provided. Most claims are not supported by the label (absent_from_label); one area (neomycin sensitization) is partially supported by the label. Overall alignment with the prescribing information is limited and indicates substantial mismatch.
Category Scores
Accurate Statements
Label notes topical antibiotics, particularly neomycin sulfate, may cause cutaneous sensitization.
Warnings/Adverse Reactions
Unsupported Statements
Neosporin is designed for minor cuts, scrapes, and burns.
Label provided covers NEOSPORIN Ophthalmic Ointment for superficial eye infections; no skin wound indications are stated.
For deep wounds—those penetrating muscle, fat, or bone, or longer than 1/2 inch—it's not safe or effective.
Label does not provide guidance on skin wounds; ophthalmic indication is limited to superficial eye infections.
Deep wounds risk infection from bacteria deeper in tissue, and Neosporin's topical action doesn't reach there.
No label guidance on wound depth or efficacy for skin wounds; ophthalmic indication is limited to superficial eye infections.
Medical guidelines from the American Academy of Dermatology and Mayo Clinic advise against it, favoring wound irrigation, cleaning, and professional closure like stitches.
Label does not reference external guidelines or wound closure recommendations.
Applying Neosporin to deep wounds can trap bacteria, delay healing, and promote resistance to neomycin.
No label guidance on deep wounds; ophthalmic indication is limited to superficial eye infections.
It may also mask infection signs, leading to abscesses or sepsis.
Label does not discuss masking signs of infection or progression to abscesses or sepsis for ophthalmic ointment.
A Cochrane review confirms they cut infection risk by 50% in minor wounds.
Label does not reference Cochrane reviews or wound infection risk data; ophthalmic indication is limited to superficial eye infections.
A Cochrane review states they add no benefit—and potential harm—in deeper or surgical ones.
No Cochrane review data is provided in the ophthalmic label sections.
Petroleum jelly or plain bacitracin is safer for superficial use, but skip for deep ones.
No guidance on petroleum jelly or bacitracin for skin use is present in the ophthalmic label.
Contradictions
Important Omissions
No skin wound indication or management guidance; label is limited to ophthalmic superficial eye infections. No skin-use dosage or administration instructions are provided.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Most claims refer to non-label skin-use; however, the ophthalmic label notes potential for cutaneous sensitization with neomycin and rare serious reactions.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Claims largely describe skin-wound use not covered by the ophthalmic label; only neomycin sensitization is partially aligned with the label.
Suggested Improvement
Limit claims to the ophthalmic indication; avoid general wound-care statements; if discussing safety, reference label-identified sensitization risks and rare adverse events.